{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T16:32:02Z","timestamp":1763224322164,"version":"3.37.3"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Zhejiang Provincial Natural Science Foundation of China","award":["LYY19H310007"],"award-info":[{"award-number":["LYY19H310007"]}]},{"name":"Medical Health Science and Technology Project of Zhejiang Provincial Health Commission","award":["2019KY448"],"award-info":[{"award-number":["2019KY448"]}]},{"name":"Project of Wenzhou Science and Technology Bureau","award":["Y2020184","Y20210221"],"award-info":[{"award-number":["Y2020184","Y20210221"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>Our study is to investigate the effects of triazole antifungal drugs on the pharmacokinetics of lorlatinib in rats.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The samples were precipitated with methanol. Chromatographic separation was performed on a ultra-performance liquid chromatography (UPLC) system using a BEH C18 column. The mobile phase consisted of 0.1% formic acid water and methanol. Lorlatinib and crizotinib (internal standard) were detected in multiple reaction monitoring mode. The fragment ions were 407.3\u2013228.07 for lorlatinib and m\/z 450.3\u2013260.0 for crizotinib. Lorlatinib and different triazole antifungal drugs were given to Sprague Dawley rats by gavage, and blood was collected from the tail vein at a certain time point. The validated UPLC\u2013MS\/MS method was applied to a drug interaction study of ketoconazole, voriconazole, itraconazole, and posaconazole with lorlatinib in rats.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Ketoconazole and voriconazole significantly inhibited lorlatinib metabolism. When administration with ketoconazole and voriconazole, the area under the curve from time zero to infinity of lorlatinib increased by 49.0% and 104.3%, respectively; the clearance decreased by 40.0% and 40.0%, respectively. While itraconazole and posaconazole did not affect lorlatinib pharmacokinetics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The UPLC-MS\/MS-based assay is helpful to further understand the pharmacokinetics of lorlatinib in rats, and confirmed the findings that the combination of lorlatinib with CYP3A inhibitors should be avoided as predicted by our pre-clinical studies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jpp\/rgad105","type":"journal-article","created":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T16:46:21Z","timestamp":1703695581000},"page":"115-121","source":"Crossref","is-referenced-by-count":2,"title":["Potential interactions between triazole antifungal agents and lorlatinib based on ultra-performance liquid chromatography-tandem mass spectrometry in rat plasma"],"prefix":"10.1093","volume":"76","author":[{"given":"Zhongjiang","family":"Ye","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou, 325000 Zhejiang ,","place":["China"]},{"name":"School of Pharmaceutical Sciences, Wenzhou Medical University , Wenzhou, 325000 Zhejiang ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8982-174X","authenticated-orcid":false,"given":"Chenxiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou, 325000 Zhejiang ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongqi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou, 325000 Zhejiang ,","place":["China"]},{"name":"School of Pharmaceutical Sciences, Wenzhou Medical University , Wenzhou, 325000 Zhejiang ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou, 325000 Zhejiang ,","place":["China"]},{"name":"School of Pharmaceutical Sciences, Wenzhou Medical University , Wenzhou, 325000 Zhejiang ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhui","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou, 325000 Zhejiang ,","place":["China"]},{"name":"School of Pharmaceutical Sciences, Wenzhou Medical University , Wenzhou, 325000 Zhejiang ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yizhang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou, 325000 Zhejiang ,","place":["China"]},{"name":"School of Pharmaceutical Sciences, Wenzhou Medical University , Wenzhou, 325000 Zhejiang ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou, 325000 Zhejiang ,","place":["China"]},{"name":"School of Pharmaceutical Sciences, Wenzhou Medical University , Wenzhou, 325000 Zhejiang ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou, 325000 Zhejiang ,","place":["China"]},{"name":"School of Pharmaceutical Sciences, Wenzhou Medical University , Wenzhou, 325000 Zhejiang ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou, 325000 Zhejiang ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aifang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou, 325000 Zhejiang ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuhua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Clinical Research Center, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou, 325000 Zhejiang ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziye","family":"Zhou","sequence":"additional","affiliation":[{"name":"Clinical Research Center, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou, 325000 Zhejiang ,","place":["China"]},{"name":"Key Laboratory of Intelligent Treatment and Life Support for Critical Diseases of Zhejiang Province , Wenzhou, 325000 Zhejiang ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"2024103012041958900_CIT0001","first-page":"103194","article-title":"Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives","volume-title":"Crit Rev Oncol Hematol","author":"Imyanitov","year":"2021"},{"key":"2024103012041958900_CIT0002","first-page":"423","article-title":"ALK-rearrangement in non-small-cell lung cancer (NSCLC)","volume-title":"Thoracic Cancer","author":"Du","year":"2018"},{"key":"2024103012041958900_CIT0003","first-page":"52","article-title":"The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)","volume-title":"Mol Cancer","author":"Golding","year":"2018"},{"key":"2024103012041958900_CIT0004","first-page":"1370","article-title":"ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer","volume-title":"J Clin Oncol","author":"Shaw","year":"2019"},{"key":"2024103012041958900_CIT0005","first-page":"3593","article-title":"Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the phase III CROWN study","volume-title":"J Clin Oncol","author":"Solomon","year":"2022"},{"key":"2024103012041958900_CIT0006","first-page":"67","article-title":"Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: subgroup analysis of a global phase 2 trial","volume-title":"Lung Cancer (Amsterdam, Netherlands)","author":"Soo","year":"2022"},{"key":"2024103012041958900_CIT0007","first-page":"1654","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume-title":"Lancet Oncol","author":"Solomon","year":"2018"},{"key":"2024103012041958900_CIT0008","first-page":"816","article-title":"Lorlatinib for previously treated ALK-positive advanced NSCLC: primary efficacy and safety from a phase 2 study in People\u2019s Republic of China","volume-title":"J Thoracic Oncol","author":"Lu","year":"2022"},{"key":"2024103012041958900_CIT0009","first-page":"1663","article-title":"Pharmacokinetic-based drug-drug interactions with anaplastic lymphoma kinase inhibitors: a review","volume-title":"Drug Design Dev Ther","author":"Zhao","year":"2020"},{"key":"2024103012041958900_CIT0010","first-page":"1254","article-title":"Metabolism, excretion, and pharmacokinetics of lorlatinib (PF-06463922) and evaluation of the impact of radiolabel position and other factors on comparability of data across 2 ADME studies","volume-title":"J Clin Pharmacol","author":"Stypinski","year":"2020"},{"volume-title":"StatPearls","year":"2023","author":"Sinawe","key":"2024103012041958900_CIT0011"},{"key":"2024103012041958900_CIT0012","first-page":"271","article-title":"Invasive fungal infection","volume-title":"Dtsch Arztebl Int","author":"von Lilienfeld-Toal","year":"2019"},{"key":"2024103012041958900_CIT0013","first-page":"2405","article-title":"Triazole antifungal agents in invasive fungal infections: a comparative review","volume-title":"Drugs","author":"Lass-Fl\u00f6rl","year":"2011"},{"key":"2024103012041958900_CIT0014","first-page":"637","article-title":"Comparative efficacy of antifungal agents used in the treatment of oropharyngeal candidiasis among HIV-infected adults: a systematic review and network meta-analysis","volume-title":"J Fungi (Basel, Switzerland)","author":"Rajadurai","year":"2021"},{"key":"2024103012041958900_CIT0015","first-page":"626897","article-title":"In vivo pharmacokinetic drug-drug interaction studies between fedratinib and antifungal agents based on a newly developed and validated UPLC\/MS-MS method","volume-title":"Front Pharmacol","author":"Tang","year":"2021"},{"key":"2024103012041958900_CIT0016","first-page":"2171","article-title":"Development of UPLC-MS\/MS method for studying the pharmacokinetic interaction between dasatinib and posaconazole in rats","volume-title":"Drug Des Dev Ther","author":"Yang","year":"2021"},{"key":"2024103012041958900_CIT0017","first-page":"689","article-title":"Effects of ketoconazole, voriconazole, and itraconazole on the pharmacokinetics of apatinib in rats","volume-title":"Drug Dev Ind Pharm","author":"Lou","year":"2019"},{"key":"2024103012041958900_CIT0018","first-page":"2405","article-title":"Triazole antifungal agents in invasive fungal infections: a comparative review","volume-title":"Drugs","author":"Lass-Fl\u00f6rl","year":"2011"},{"key":"2024103012041958900_CIT0019","first-page":"131","article-title":"The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participants","volume-title":"Invest New Drugs","author":"Patel","year":"2020"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/76\/2\/115\/60221401\/rgad105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/76\/2\/115\/60221401\/rgad105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T16:24:15Z","timestamp":1730305455000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/76\/2\/115\/7502517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,1]]},"published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jpp\/rgad105","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"type":"print","value":"0022-3573"},{"type":"electronic","value":"2042-7158"}],"subject":[],"published-other":{"date-parts":[[2024,2,1]]},"published":{"date-parts":[[2024,2,1]]}}}